Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 3:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 908 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Macular Degeneration, Age-related Clear all
Completed Phase 1 Interventional

Laser and Medical Treatment of Diabetic Macular Edema

NCT00027287
View directory record Official record
Conditions
Diabetes Mellitus, Macular Edema
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 3:14 PM EDT
Recruiting No phase listed Observational

Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study

NCT07556406
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy
Interventions
Optical coherence tomography, Microperimetry
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 1 Interventional

Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)

NCT01997164
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions
REGN910-3, REGN910, Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Beverly Hills, California • Winter Haven, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 14, 2026, 3:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

NCT06550011
View directory record Official record
Conditions
Neovascular (Wet) AMD
Interventions
ABI-110 Low Dose, ABI-110 Medium Dose, ABI-110 High Dose
Drug
Lead sponsor
Avirmax Biopharma Inc
Industry
Eligibility
50 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
4
States / cities
Bakersfield, California • Walnut Creek, California • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 14, 2026, 3:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

NCT04339764
View directory record Official record
Conditions
Dry Age-Related Macular Degeneration, Geographic Atrophy
Interventions
iPSC-derived RPE/PLGA transplantation
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

NCT05282004
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
SOK583A1
Drug
Lead sponsor
Sandoz
Industry
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
5
States / cities
Poway, California • Marietta, Georgia • Oak Forest, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Not applicable Interventional Results available

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

NCT01640171
View directory record Official record
Conditions
Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
Procedure · Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 2 Interventional Results available

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

NCT02713204
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
REGN910-3, Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
87
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration

NCT01922128
View directory record Official record
Conditions
Nonexudative Age-related Macular Degeneration
Interventions
MC-1101, Placebo
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

NCT04894071
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
QA102, Placebo
Drug
Lead sponsor
Smilebiotek Zhuhai Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 14, 2026, 3:14 PM EDT
Active, not recruiting No phase listed Observational

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT06161584
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
34
States / cities
Bakersfield, California • Beverly Hills, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Not applicable Interventional

Technology-based Eye Care Services (TECS) Compare

NCT02558712
View directory record Official record
Conditions
Cataract, Macular Degeneration, Glaucoma
Interventions
Technology-based Eye Care Services (TECS) Protocol
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 1Phase 2 Interventional

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

NCT04567303
View directory record Official record
Conditions
Macular Degeneration
Interventions
Zifibancimig, Ranibizumab, Port Delivery Platform
Drug · Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
36
States / cities
Mesa, Arizona • Phoenix, Arizona • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 14, 2026, 3:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance

NCT06619405
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Streetlab VR
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
50 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

NCT01134055
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib eye drops, placebo, ranibizumab intravitreal injection
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Oct 14, 2026, 3:14 PM EDT
Completed No phase listed Observational

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

NCT05037396
View directory record Official record
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Brolucizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
9,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 4 Interventional Results available

Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment

NCT00543296
View directory record Official record
Conditions
Uveitis
Interventions
0.59 mg Fluocinolone Acetonide implant
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 1Phase 2 Interventional

A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD

NCT00793923
View directory record Official record
Conditions
Exudative Age-Related Macular Degeneration
Interventions
ranibizumab and dexamethasone, Ranibizumab
Drug
Lead sponsor
Subhransu K. Ray, M.D., Ph.D.
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.

NCT01449682
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
Ozurdex
Drug
Lead sponsor
Retina Macula Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 14, 2026, 3:14 PM EDT
Active, not recruiting No phase listed Observational

Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study

NCT06048185
View directory record Official record
Conditions
Stargardt Disease
Interventions
Gene Therapy Product-MCO-010
Biological
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
16 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Miami, Florida • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 14, 2026, 3:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lucentis for Treatment of Macular Edema

NCT00464581
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Not listed
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
Up to 90 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 14, 2026, 3:14 PM EDT
Completed Not applicable Interventional Results available

Translation of Eye Movement Reading Training to Clinical Practice

NCT01853930
View directory record Official record
Conditions
Macular Disease
Interventions
Platform for Administering Eye-movement Control Training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 14, 2026, 3:14 PM EDT
Completed No phase listed Observational

AMD Ryan Initiative Study (ARIS)

NCT03092492
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 3:14 PM EDT
Recruiting No phase listed Observational

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

NCT07144137
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Complement Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Mountain View, California • Oak Forest, Illinois • Springfield, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 3:14 PM EDT